Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT9283 in Refractory Hematological Malignancies
NCT00522990Phase 2Terminated
- Sponsor
- Astex Pharmaceuticals
- Start
- Sep 2006
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AT9283 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), myelofibrosis (MF), sponsored by Astex Pharmaceuticals. Started Sep 2006; status: terminated.
02
Drugs
AT9283
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00522990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522990.